163 related articles for article (PubMed ID: 11279191)
1. Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity.
Nickerson K; Sisk TJ; Inohara N; Yee CS; Kennell J; Cho MC; Yannie PJ; Nunez G; Chang CH
J Biol Chem; 2001 Jun; 276(22):19089-93. PubMed ID: 11279191
[TBL] [Abstract][Full Text] [Related]
2. Self-association of CIITA and its transactivation potential.
Sisk TJ; Roys S; Chang CH
Mol Cell Biol; 2001 Aug; 21(15):4919-28. PubMed ID: 11438649
[TBL] [Abstract][Full Text] [Related]
3. Degradation, Promoter Recruitment and Transactivation Mediated by the Extreme N-Terminus of MHC Class II Transactivator CIITA Isoform III.
Beaulieu YB; Leon Machado JA; Ethier S; Gaudreau L; Steimle V
PLoS One; 2016; 11(2):e0148753. PubMed ID: 26871568
[TBL] [Abstract][Full Text] [Related]
4. CIITA promoter I CARD-deficient mice express functional MHC class II genes in myeloid and lymphoid compartments.
Zinzow-Kramer WM; Long AB; Youngblood BA; Rosenthal KM; Butler R; Mohammed AU; Skountzou I; Ahmed R; Evavold BD; Boss JM
Genes Immun; 2012 Jun; 13(4):299-310. PubMed ID: 22218223
[TBL] [Abstract][Full Text] [Related]
5. CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.
Hake SB; Masternak K; Kammerbauer C; Janzen C; Reith W; Steimle V
Mol Cell Biol; 2000 Oct; 20(20):7716-25. PubMed ID: 11003667
[TBL] [Abstract][Full Text] [Related]
6. The histone acetyltransferase domains of CREB-binding protein (CBP) and p300/CBP-associated factor are not necessary for cooperativity with the class II transactivator.
Harton JA; Zika E; Ting JP
J Biol Chem; 2001 Oct; 276(42):38715-20. PubMed ID: 11514574
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
8. The MHC class II transactivator (CIITA) requires conserved leucine charged domains for interactions with the conserved W box promoter element.
Brown JA; Rogers EM; Boss JM
Nucleic Acids Res; 1998 Sep; 26(18):4128-36. PubMed ID: 9722631
[TBL] [Abstract][Full Text] [Related]
9. A novel CARD containing splice-isoform of CIITA regulates nitric oxide synthesis in dendritic cells.
Huang D; Lim S; Chua RY; Shi H; Ng ML; Wong SH
Protein Cell; 2010 Mar; 1(3):291-306. PubMed ID: 21203976
[TBL] [Abstract][Full Text] [Related]
10. Class II transactivator promoter activity is suppressed through regulation by a trophoblast noncoding RNA.
Geirsson A; Paliwal I; Lynch RJ; Bothwell AL; Hammond GL
Transplantation; 2003 Jul; 76(2):387-94. PubMed ID: 12883198
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells.
Satoh A; Toyota M; Ikeda H; Morimoto Y; Akino K; Mita H; Suzuki H; Sasaki Y; Kanaseki T; Takamura Y; Soejima H; Urano T; Yanagihara K; Endo T; Hinoda Y; Fujita M; Hosokawa M; Sato N; Tokino T; Imai K
Oncogene; 2004 Nov; 23(55):8876-86. PubMed ID: 15467734
[TBL] [Abstract][Full Text] [Related]
12. Positive regulatory domain I (PRDM1) and IRF8/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation.
Smith MA; Wright G; Wu J; Tailor P; Ozato K; Chen X; Wei S; Piskurich JF; Ting JP; Wright KL
J Biol Chem; 2011 Mar; 286(10):7893-7904. PubMed ID: 21216962
[TBL] [Abstract][Full Text] [Related]
13. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.
Lu HT; Riley JL; Babcock GT; Huston M; Stark GR; Boss JM; Ransohoff RM
J Exp Med; 1995 Nov; 182(5):1517-25. PubMed ID: 7595221
[TBL] [Abstract][Full Text] [Related]
14. Cis-element dependence and occupancy of the human invariant chain promoter in CIITA-dependent and -independent transcription.
Tai AK; Zhou G; Chau K; Ono SJ
Mol Immunol; 1999 May; 36(7):447-60. PubMed ID: 10449097
[TBL] [Abstract][Full Text] [Related]
15. CIITA-induced occupation of MHC class II promoters is independent of the cooperative stabilization of the promoter-bound multi-protein complexes.
Villard J; Muhlethaler-Mottet A; Bontron S; Mach B; Reith W
Int Immunol; 1999 Mar; 11(3):461-9. PubMed ID: 10221658
[TBL] [Abstract][Full Text] [Related]
16. Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA.
Pan H; O'Brien TF; Wright G; Yang J; Shin J; Wright KL; Zhong XP
J Immunol; 2013 Jul; 191(2):699-707. PubMed ID: 23776173
[TBL] [Abstract][Full Text] [Related]
17. A 36-amino-acid region of CIITA is an effective inhibitor of CBP: novel mechanism of gamma interferon-mediated suppression of collagen alpha(2)(I) and other promoters.
Zhu XS; Ting JP
Mol Cell Biol; 2001 Oct; 21(20):7078-88. PubMed ID: 11564890
[TBL] [Abstract][Full Text] [Related]
18. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency.
Zhou H; Glimcher LH
Immunity; 1995 May; 2(5):545-53. PubMed ID: 7749985
[TBL] [Abstract][Full Text] [Related]
19. Class II transactivator suppresses transcription of thyroid-specific genes.
Mori-Aoki A; Pietrarelli M; Nakazato M; Caturegli P; Kohn LD; Suzuki K
Biochem Biophys Res Commun; 2000 Nov; 278(1):58-62. PubMed ID: 11071855
[TBL] [Abstract][Full Text] [Related]
20. Role of PU.1 in MHC class II expression through transcriptional regulation of class II transactivator pI in dendritic cells.
Kitamura N; Yokoyama H; Yashiro T; Nakano N; Nishiyama M; Kanada S; Fukai T; Hara M; Ikeda S; Ogawa H; Okumura K; Nishiyama C
J Allergy Clin Immunol; 2012 Mar; 129(3):814-824.e6. PubMed ID: 22112519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
